‘Katja is a highly professional PR expert. She is extremely well networked, has a strong understanding of the PR processes in life sciences and has repeatedly delivered high quality outcomes for client companies.’
Douglas Thomson
CEO of Pneumagen
Objectives
- To position Pneumagen’s platform technology as delivering value in treating infectious diseases, including COVID-19, by targeting the human glycome, leading to raised awareness with potential partners and investors
- To highlight Pneumagen’s Neumifil™ as a potential anti-viral for the the treatment of COVID-19 with the local Scottish media
- Raising awareness of the company’s £4 million fundraising to support clinical trials in COVID-19
Strategy
- Supported development of new corporate materials, such as a new website, investor deck and press releases and setting up social media strategy
- Coordinated communications activities with third parties including the University of St Andrews and local investors
- Drafting press releases and associated key messaging, leveraging relationship with St Andrews’ to support local Scottish science story
Results
- Secured significant coverage in Scottish national and broadcast media, showing the company is committed to supporting the global effort to treat the coronavirus pandemic
- Supported a GBP 4m investment in May to progress Neumifil™ as a treatment for Covid-19 in human clinical trials
